| 摘要 |
Methods of treating disorders related to CXCL13 activity utilize CXCL13 antagonists and, optionally, TNFαantagonists, such as antibodies, including specified portions or variants, polypeptides, polynucleotides, siRNA, shRNA, ribozymes, and DNAzymes. Disorders related to CXCL13 activity include inflammatory disorders, such as pulmonary disorders, for example, asthma, emphysema, and COPD, and systemic lupus erythematosus. |
